
Around 750 million people live with asthma or chronic obstructive pulmonary disease (COPD), yet most lack access to affordable, appropriate inhaled medicines to keep them healthy, out of hospital and at work or school. This gap imposes enormous health and economic costs on families and health systems. Drawing on insulin access experience in Kenya, Kyrgyzstan, Peru, and Tanzania, this report examines what lung health can learn from diabetes care and recommends a new approach to expanding access.
Enhancing Access to Inhaled Medicines: Lessons from Insulin Access is a collaboration between the International Union Against Tuberculosis and Lung Disease (The Union), the Forum of International Respiratory Societies, and the NCD Policy Lab at the University of Geneva.
Written by Alstonia Impact and funded by the Swiss Agency for Development and Cooperation, the report draws on over 240 documents, 15 expert interviews and studies in Kenya, Kyrgyzstan, Peru and Tanzania.